|
|
Prospects for the Commercialization of Human Monoclonal AntibodiesPublished by: CHI Insight Pharma Reports Published: Dec. 1, 2002 - 206 Pages Table of Contents1. Introduction and Overview of Monoclonal Antibodies
2.2 “Off-the-Shelf” Antibodies and Companies 2.3 Applications of Proprietary Monoclonal Antibody Technology in Research/Drug Discovery
3.2 Improving Monoclonal Antibodies: Technologies and Companies 3.3 Currently Available Monoclonal Antibody Diagnostics and Therapies 3.4 Disease Applications of Monoclonal Antibody-Based Therapeutics 3.5 Emerging Therapies: Naked Antibodies as Therapeutic Agents 3.5.1 Unconjugated Monoclonal Antibodies 3.5.2 Anti-Idiotype Monoclonal Antibodies 3.6 Emerging Therapies: Targeting Therapy with Monoclonal Antibodies 3.6.1 Delivery of Radioisotopes 3.6.1.1 Radioimmunodiagnostics 3.6.1.2 Radioimmunnotherapy 3.6.2 Delivery of Cytotoxic Drugs 3.6.3 Immunotoxins 3.6.4 Enzyme Prodrug Therapy 3.6.5 Other Fusion Proteins
Walter Blättler, ImmunoGen, Inc. Carl Borrebaeck, Lund University Neil M. Cowen, Epicyte Pharmaceutical, Inc. Alex Duncan, Cambridge Antibody Technology Nils Lonberg, Medarex Gayle Mills, Abgenix, Inc. Mitchell E. Reff, IDEC Pharmaceuticals Corporation Clay B. Siegall, Seattle Genetics, Inc.
Abgenix Affibody AltaRex BioInvent Biosite Biovation Cambridge Antibody Technology (CAT) Celltech Group Domantis Dyax Enzon Epicyte Genentech GenWay Biotec Genzyme Molecular Oncology IDEC Pharmaceuticals ImmunoGen Medarex/Genmab MedImmune MorphoSys Peregrine Pharmaceuticals Protein Design Labs (PDL) Seattle Genetics Viventia Biotech
AbstractThe market for monoclonal antibodies has grown significantly, resulting in numerous companies pursuing a wide variety of approaches to applying monoclonal antibody technology to both therapeutic and nontherapeutic applications. Increasingly, small biotech and genomic companies with a wealth of targets and a desire to reap the benefits of developing their own drugs are partnering with major antibody developers, as well as smaller companies that can convert those targets into potential antibody drugs. This strategy—which provides a relatively low cost, low risk mode of entry into the pharmaceutical business—is perhaps the largest factor driving the therapeutic antibody field.Prospects for the Commercialization of Human Monoclonal Antibodies is based on interviews with leading experts in the field who express their views on the applications and future prospects of current and emerging monoclonal antibodies for therapy, drug discovery research, and in vivo diagnostics. The report begins with an evaluation of the efforts of companies that are developing antibody-based research applications, including the use of monoclonal antibodies in target characterization and validation, in diagnostics, on protein arrays—one of the fastest-growing areas in protein analysis, and in many other applications. The report then examines monoclonal antibodies currently used in diagnostics and therapeutics, and discusses the activities of many companies that are pursuing various approaches to applying monoclonal antibody technology to therapeutic applications for treating cancer and other major diseases. While all of the therapeutic antibodies to reach the market to date are murine, chimeric, or humanized antibodies, several companies are developing fully human monoclonal antibodies. For example, both Abgenix and Medarex have developed transgenic mice that can produce human antibodies, and several pharmaceutical and biopharmaceutical companies have entered into agreements with Abgenix and Medarex to gain access to this technology. An alternate approach being used by Cambridge Antibody Technology and other companies is to isolate fully human variable domains from phage libraries, and then convert these into monoclonal antibodies. |
|
|||
|
About MarketResearch.com
|
||||